IMC Chicago’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$90.9M Sell
1,895,100
-191,100
-9% -$8.21M 0.02% 397
2026
Q1
$76.7M Sell
2,086,200
-302,400
-13% -$14.3M 0.03% 363
2025
Q4
$122M Buy
2,388,600
+354,600
+17% +$18.1M 0.04% 256
2025
Q3
$113M Buy
2,034,000
+922,900
+83% +$54M 0.04% 253
2025
Q2
$76.7M Buy
1,111,100
+229,200
+26% +$15.6M 0.03% 286
2025
Q1
$61.2M Sell
881,900
-413,300
-32% -$34.1M 0.03% 269
2024
Q4
$111M Buy
1,295,200
+779,300
+151% +$84.3M 0.05% 188
2024
Q3
$61.4M Buy
515,900
+68,200
+15% +$9.1M 0.03% 262
2024
Q2
$63.9M Sell
447,700
-41,600
-9% -$5.51M 0.04% 242
2024
Q1
$62.8M Buy
489,300
+277,400
+131% +$33M 0.04% 210
2023
Q4
$21.9M Buy
211,900
+63,300
+43% +$6.26M 0.01% 431
2023
Q3
$13.5M Buy
+148,600
New +$13.1M 0.01% 473

Other funds holding NVO

IMC Chicago's NVO Position: Q2 2026 in Review

IMC Chicago sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 802,198 shares — an estimated $34.5M sold.

IMC Chicago first reported a position in NVO in Q3 2024 and held it in 7 quarters. The position peaked at $29.5M in Q1 2026. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • IMC Chicago reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 802,198 Novo Nordisk shares in Q2 2026, an estimated $34.5M.
  • IMC Chicago first reported a position in Novo Nordisk in Q3 2024 and held it in 7 quarters.
  • IMC Chicago's Novo Nordisk position peaked at $29.5M in Q1 2026.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.